MediPrint Ophthalmics Expands Clinical Program to Address Contact Lens Dropout Due to Discomfort

SAN DIEGO--(BUSINESS WIRE)--MediPrint® Ophthalmics, a clinical-stage ophthalmic drug delivery company, is accelerating a new clinical program aimed at tackling one of the largest challenges in contact lens wear—discomfort-related dropout. Building on promising clinical and in-vitro results, MediPrint is leveraging its proprietary 3D-printing, drug delivering contact lens technology to enhance comfort and reduce dropout rates among lens wearers.

Every year, 15-20% of contact lens users discontinue wear, with about 50% citing discomfort as the primary reason. This significant unmet need presents a major opportunity for innovation. The company's latest clinical trial demonstrated that its contact lenses, which incorporate sustained hyaluronic acid (HA) delivery, can significantly improve wearer comfort. In the LL-BMT1 trial, patients reported a 38% improvement in comfort and a 40% reduction in dry eye symptoms, as measured by the CLDEQ-8 questionnaire.

“Our clinical study results reinforce the potential of our technology to not only address medical conditions like glaucoma but also fundamentally improve the comfort of contact lenses for millions of wearers,” said Praful Doshi, Founder and CEO of MediPrint Ophthalmics. “By expanding into the broader contact lens market, we aim to recapture the significant portion of patients who have abandoned lenses due to discomfort.”

MediPrint’s technology delivers HA continuously, ensuring sustained hydration and comfort throughout the lens wear time. Unlike conventional eye drops, which provide only temporary relief, this novel approach raises the base comfort level of any contact lens.

Looking Ahead: Bringing Comfort to More Lens Wearers

With this expansion, MediPrint plans to develop its comfort-enhancing technology for use in both daily disposable lenses and weekly disposable lenses, giving patients greater flexibility while reducing discomfort-related dropouts. The company aims to bring this innovative solution to market alongside its ongoing Phase 3 clinical program for glaucoma treatment.

“As we move forward, our mission remains clear—to improve vision care by integrating convenience, comfort, and therapeutic benefits into a single platform,” said Doshi. “We are excited to bring a much-needed solution to the millions of people who struggle with contact lens discomfort.”

For more information about MediPrint Ophthalmics and its innovative drug-eluting contact lenses, visit www.mediprintlens.com.

About MediPrint® Ophthalmics

MediPrint® Ophthalmics is a San Diego-based clinical-stage eye care pharmaceutical company dedicated to enhancing vision for life. The company pioneers drug-eluting contact lenses that deliver therapeutics directly to the eye, providing comfortable, convenient, preservative-free alternatives to traditional eye drop treatments. MediPrint’s portfolio is designed to address major eye conditions, including glaucoma, myopia, dry eye, and discomfort associated with contact lens use.